Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the κ2B (enkephalin-sensitive) binding site

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Peptides

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0196-9781(93)90005-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats.

  1991cited by this paper
• The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat.

  1991cited by this paper
• Effect of phenylpiperidine opioid antagonists on food consumption and weight gain of the obese Zucker rat.

  1990cited by this paper
• Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.

  1990cited by this paper
• An approach to the development of drugs for appetite disorders.

  1989cited by this paper
• Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype.

  1989cited by this paper
• Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors.

  1988cited by this paper
• [3H]U-69593 labels a subtype of kappa opiate receptor with characteristics different from that labeled by [3H]ethylketocyclazocine.

  1988cited by this paper
• Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.

  1988cited by this paper
• beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.

  1988cited by this paper
• LY164929: a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site.

  1988cited by this paper
• Neuroadaptation of rats to kappa agonists U-50,488 and tifluadom.

  1988cited by this paper
• Feeding elicited by dynorphin (1-13) microinjections into the ventral tegmental area in rats.

  1988cited by this paper
• Autoradiography of [3H]U-69593 binding sites in rat brain: evidence for κ opioid receptor subtypes

  1988cited by this paper
• Beneficial effects of the κ opioid receptor agonist U-50488H in experimental acute brain and spinal cord injury

  1987cited by this paper
• Psychotomimesis mediated by kappa opiate receptors

  1986cited by this paper
• Binding characteristics of kappa opioids in rat brain. A comparison of in vitro binding paradigms.

  1985cited by this paper
• Interaction of Opiates with Opioid Binding Sites in the Bovine Adrenal Medulla: I. Interaction with δ and μ Sites

  1985cited by this paper
• Kappa 3: a novel subtype of the kappa opioid site in bovine adrenal medulla, highly selective for Met-enkephalin-Arg6-Phe7.

  1984cited by this paper
• U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

  1983cited by this paper
• A kappa opioid effect: increased urination in the rat.

  1983cited by this paper
• Opioid modulation of appetite.

  1983cited by this paper
• Evidence for multiple "Kappa" binding sites by use of opioid peptides in the guinea-pig lumbo-sacral spinal cord.

  1982cited by this paper
• Statistical characterization of the random errors in the radioimmunoassay dose--response variable.

  1976cited by this paper

• Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats

  2019cites this paper
• Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists

  2016influential citation
• Central Analgesic Activity

  2016cites this paper
• Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor

  2016influential citation
• Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain

  2007cites this paper
• In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.

  2007cites this paper
• Autonomic dysregulation and the metabolic syndrome: pathologic partners in an emerging global pandemic.

  2006cites this paper
• Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome

  2004cites this paper
• Insulin resistance and the sympathetic nervous system

  2003cites this paper
• Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist.

  2003cites this paper
• Analgesic, anti-inflammatory, and anti-pyretic activity1

  2002cites this paper
• The Effect of Opioid Antagonismon Food Intake Behavior and Body Weight in a Biobehavioral Model of Obese Binge Eating

  2002cites this paper
• Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay

  1999cites this paper
• Opioid peptide receptor studies. 10. Nor‐BNI differentially inhibits kappa receptor agonist‐induced G‐protein activation in the guinea pig caudate: Further evidence of kappa receptor heterogeneity

  1999cites this paper
• U-50,488 and the к receptor Part II: 1991–1998

  1999cites this paper
• β-Casomorphins Stimulate and Enterostatin Inhibits the Intake of Dietary Fat in Rats

  1998cites this paper
• Analgesic, anti-inflammatory, and antipyretic activity

  1997cites this paper
• 6β‐[125Iodo]‐3, 14‐dihydroxy‐17‐methyl‐4, 5α‐epoxymorphinan ([125I]IOXY‐AGO): A potent and selective radioligand for opioid μ receptors

  1995cites this paper
• Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the κ2 receptor in guinea pig brain

  1995cites this paper
• Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-famide (NPFF) and A-18-famide, for opioid μ, δ, κ1, κ2a, or κ2b receptors

  1994cites this paper